Last reviewed · How we verify
oral anti-acid treatment
oral anti-acid treatment is a Small molecule drug developed by University of British Columbia. It is currently FDA-approved. Also known as: Silver Nitrate, Dermabond.
At a glance
| Generic name | oral anti-acid treatment |
|---|---|
| Also known as | Silver Nitrate, Dermabond |
| Sponsor | University of British Columbia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial) (PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (PHASE3)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral anti-acid treatment CI brief — competitive landscape report
- oral anti-acid treatment updates RSS · CI watch RSS
- University of British Columbia portfolio CI
Frequently asked questions about oral anti-acid treatment
What is oral anti-acid treatment?
oral anti-acid treatment is a Small molecule drug developed by University of British Columbia.
Who makes oral anti-acid treatment?
oral anti-acid treatment is developed and marketed by University of British Columbia (see full University of British Columbia pipeline at /company/university-of-british-columbia).
Is oral anti-acid treatment also known as anything else?
oral anti-acid treatment is also known as Silver Nitrate, Dermabond.
What development phase is oral anti-acid treatment in?
oral anti-acid treatment is FDA-approved (marketed).
Related
- Manufacturer: University of British Columbia — full pipeline
- Also known as: Silver Nitrate, Dermabond
- Compare: oral anti-acid treatment vs similar drugs
- Pricing: oral anti-acid treatment cost, discount & access